 | |
| Clinical data | |
|---|---|
| Other names | Selandopam; (–)-(S)-7,8-Dihydroxy-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline; 7,8-DDPTI; YM-435; YM435; MYD-37; MYD37 |
| Routes of administration | Intravenous administration |
| Drug class | DopamineD1-like receptoragonists |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H15NO4 |
| Molar mass | 273.288 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zelandopam (INNTooltip International Nonproprietary Name; developmental code namesYM-435,MYD-37) is aselectivedopamineD1-like receptoragonist related tofenoldopam which was under development inJapan for the treatment ofhypertension andheart failure but was never marketed.[1][2][3] The drug was being developed for use byintravenous administration.[1] The development of zelandopam appears to have been discontinued by the early 2000s.[1] It was first described in thescientific literature by 1991.[4]
 | Thisantihypertensive-related article is astub. You can help Wikipedia byexpanding it. |
